These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32726824)

  • 1. Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians.
    Giustozzi M; Castellucci LA; Barnes GD
    Hamostaseologie; 2020 Aug; 40(3):292-300. PubMed ID: 32726824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants: unique properties and practical approaches to management.
    Barnes GD; Kurtz B
    Heart; 2016 Oct; 102(20):1620-6. PubMed ID: 27402803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
    Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
    Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.
    Pagès A; Sabatier R; Sallerin B
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):332-337. PubMed ID: 32266832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation: Updated Guidelines for Outpatient Management.
    Wigle P; Hein B; Bernheisel CR
    Am Fam Physician; 2019 Oct; 100(7):426-434. PubMed ID: 31573167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.
    Sarma A; Giugliano RP
    Hosp Pract (1995); 2015; 43(5):258-67. PubMed ID: 26559852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation.
    Fernández CS; Gullón A; Formiga F
    J Comp Eff Res; 2020 May; 9(7):509-523. PubMed ID: 32329353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies.
    Kim S; Namba J; Goodman AM; Nguyen T; Saunders IM
    J Oncol Pharm Pract; 2020 Mar; 26(2):351-360. PubMed ID: 31142232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study.
    Denas G; Fedeli U; Gennaro N; Ferroni E; Corti MC; Pengo V
    J Cardiovasc Med (Hagerstown); 2020 Jun; 21(6):415-419. PubMed ID: 32355064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review.
    Pallazola VA; Kapoor RK; Kapoor K; McEvoy JW; Blumenthal RS; Gluckman TJ
    Vasc Med; 2019 Apr; 24(2):141-152. PubMed ID: 30755150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing the perioperative patient on direct oral anticoagulants.
    Leitch J; van Vlymen J
    Can J Anaesth; 2017 Jun; 64(6):656-672. PubMed ID: 28429198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
    Łukasik M; Zawilska K; Undas A
    Neurol Neurochir Pol; 2015; 49(3):171-9. PubMed ID: 26048605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.
    Chan NC; Bhagirath V; Dale BJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2015 Nov; 13(11):1213-23. PubMed ID: 26471327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new era of anticoagulation.
    Skeik N; Rumery KK; Rodriguez GT
    Ann Vasc Surg; 2014 Feb; 28(2):503-14. PubMed ID: 24412298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.